Effect of paclitaxel combined with lobaplatin in the treatment of 58 patients with LACC
10.3969/j.issn.1671-8348.2018.12.018
- VernacularTitle:紫杉醇联合洛铂治疗局部晚期宫颈癌患者的疗效观察
- Author:
Na LI
1
;
Jiao XIONG
;
Jing YAN
;
Ruixue WANG
;
Lixian FU
Author Information
1. 遵义医学院附属医院妇科
- Keywords:
paclitaxel;
lobaplatin;
locally advanced cervical cancer;
neoadjuvant chemotherapy;
tumor markers;
prognosis
- From:
Chongqing Medicine
2018;47(12):1635-1638
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of paclitaxel combined with platinum on neoadjuvant chemotherapy in patients with locally advanced cervical cancer (LACC).Methods A total of 58 cases with LACC were treated with neoadjuvant chemotherapy in our hospital were selected,of which 29 patients (group A) were treated with paclitaxel plus lobaplatin and 29 patients (group B) were treated with paclitaxel plus cisplatin.Both groups received Radical cervical cancer surgery.The short-term efficacy,serum tumor markers,incidence of toxic side effects and long-term prognosis were compared between the two groups.Results The remission rate in group A was 82.75 ％ and the total effective rate was 100.00％;the remission rate in group B was 68.97％ and the total effective rate was 96.55％;there was no significant difference between the two groups (P＞0.05).After chemotherapy,serum CYFRA21-1 and SCCAg levels in patients of group A and B were significantly lower than those before chemotherapy (P＜0.05).During chemotherapy,the incidence of nausea,vomiting and diarrhea in group A was 17.24％ and 6.90 ％,respectively.The incidence of nausea,vomiting and diarrhea in group B was 48.28％ and 31.03 ％,respectively,the difference between the two groups was statistically significant (P＜0.05).After 36 months of follow-up,the overall survival rate in group A was 68.97 ％,and the overall survival rate in group B was 62.07 ％,there was no significant difference between the two groups (x2 =0.305,P =0.581);there was no significant difference in survival time between the two groups (Z=0.381,P=0.537).Conclusion The effect of Paclitaxel combined with lobaplatin in the preoperative neoadjuvant chemotherapy of LACC patients is equivalent to paclitaxel and cisplatin.
